{"created":"2023-05-15T16:32:08.077856+00:00","id":3858,"links":{},"metadata":{"_buckets":{"deposit":"8a44add9-3d8e-4e0a-9a1b-f02112b852fe"},"_deposit":{"created_by":6,"id":"3858","owners":[6],"pid":{"revision_id":0,"type":"depid","value":"3858"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00003858","sets":["10:22:24"]},"author_link":["115523","115522"],"item_5_alternative_title_19":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"ゲフィチニブの薬物動態パラメーターと無増悪生存期間・有害事象との相関"}]},"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-02-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"382","bibliographicPageStart":"377","bibliographicVolumeNumber":"78","bibliographic_titles":[{"bibliographic_title":"Cancer Chemotherapy and Pharmacology"}]}]},"item_5_date_granted_64":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2017-02-01"}]},"item_5_degree_grantor_62":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_name":"Nagasaki University (長崎大学)"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"17301","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_5_degree_name_61":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士(医学)"}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose: The relationship between plasma concentration and antitumor activity of gefitinib was assessed in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Patients and methods: \nPlasma trough levels of gefitinib were measured on days 2 (D2) and 8 (D8) by high-performance liquid chromatography in 31 patients. Plasma concentrations of gefitinib \nwere also measured 10 h after the first administration in 21 of these patients to calculate the elimination half-life of gefitinib. Results: The median trough levels were: 197 ng/ml 10 h from the first administration of gefitinib; 113 ng/ml on D2; and 358 ng/ml on D8. The median D8/D2 ratio was 2.709, and the median elimination half-life was 15.7 h. The median progression-free survival (PFS) was 273 days, and the median overall survival (OS) was 933 days. A high D8/D2 ratio was significantly correlated with better PFS, though the plasma trough levels on D2 and D8 were not significantly related to PFS. The elimination half-life was not a significant factor for PFS, but it was significantly correlated with high-grade adverse events. Pharmacokinetic parameters were not significantly correlated with OS. Conclusions: A high D8/D2 ratio, but not elimination half-life, might be a predictor of better PFS in patients with NSCLC harboring EGFR mutations treated with gefitinib. On the other hand, long elimination half-life was related to high-grade adverse events in these patients.","subitem_description_type":"Abstract"}]},"item_5_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"長崎大学学位論文 学位記番号:博(医歯薬)甲第914号 学位授与年月日:平成29年2月1日","subitem_description_type":"Other"}]},"item_5_description_69":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Nagasaki University (長崎大学), 博士(医学) (2017-02-01)","subitem_description_type":"Other"}]},"item_5_dissertation_number_65":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲医歯薬第914号"}]},"item_5_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"115523","nameIdentifierScheme":"WEKO"}],"names":[{"name":"Mizoguchi, Kosuke"}]}]},"item_5_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer"}]},"item_5_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1007/s00280-016-3097-4","subitem_relation_type_select":"DOI"}}]},"item_5_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c Springer-Verlag Berlin Heidelberg 2016"},{"subitem_rights":"The final publication is available at link.springer.com"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03445704","subitem_source_identifier_type":"ISSN"}]},"item_5_text_67":{"attribute_name":"学位の種類","attribute_value_mlt":[{"subitem_text_value":"課程博士"}]},"item_5_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"溝口, 孝輔"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-02-01"}],"displaytype":"detail","filename":"ISYK914_Mizoguchi.pdf","filesize":[{"value":"137.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ISYK914_Mizoguchi.pdf","objectType":"fulltext","url":"https://nagasaki-u.repo.nii.ac.jp/record/3858/files/ISYK914_Mizoguchi.pdf"},"version_id":"47ea81c8-6c60-4742-ab1f-df8cc096e4a3"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Chemotherapy","subitem_subject_scheme":"Other"},{"subitem_subject":"EGFR mutations","subitem_subject_scheme":"Other"},{"subitem_subject":"Elimination half-life","subitem_subject_scheme":"Other"},{"subitem_subject":"Gefitinib","subitem_subject_scheme":"Other"},{"subitem_subject":"Non-small cell lung cancer","subitem_subject_scheme":"Other"},{"subitem_subject":"Pharmacokinetics","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations","subitem_title_language":"en"}]},"item_type_id":"5","owner":"6","path":["24"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2017-02-06"},"publish_date":"2017-02-06","publish_status":"0","recid":"3858","relation_version_is_last":true,"title":["Pharmacokinetic parameters of gefitinib predict efficacy?and toxicity in patients with advanced non‐small cell lung cancer harboring EGFR mutations"],"weko_creator_id":"6","weko_shared_id":-1},"updated":"2023-08-23T04:55:21.138194+00:00"}